National
AIDS 2012: Protesters disrupt congressional panel on AIDS
Activists want to repeal ban on PEPFAR funds from going to sex workers
Protesters disrupt a congressional panel moderated by former Sen. Bill Frist (left) at the 19th International AIDS Conference (Blade photo by Chris Johnson)
Protesters disrupted an HIV/AIDS panel discussion on Wednesday involving members of Congress from both sides of the aisle, accusing the Republican senators of blocking efforts to thwart the disease at home and abroad.
The activists, many of whom were affiliated with the umbrella group called the Global Network of Sex Work Projects, stormed the dais where the members of Congress began speaking shortly after former U.S. Sen. Bill Frist, who was serving as moderator, started the event at the 19th international AIDS conference in D.C.
The session was titled, “The United States Congress & the Global AIDS Epidemic.” In addition to Frist, four sitting members of Congress took part: Rep. Barbara Lee (D-Calif.), Sen. Chris Coons (D-Del.), Sen. Mike Enzi (R-Wyo.) and Sen. Marco Rubio (R-Fla.).
Chanting “Repeal the pledge for PEPFAR” and ringing cowbells, protesters called on Congress to repeal the portion of the President’s Emergency Plan for AIDS Relief, or PEPFAR, requiring organizations that receive money under the program to have policies against prostitution — even though sex workers around the world are disproportionately affected by HIV/AIDS. Protesters later chanted, “Sex workers rights are human rights!”
Many of the protesters carried red umbrellas. Their signs read, “U.S.A. Repeal the Anti-Prostitution Pledge” and “Export Justice; Not Bad Policy.” A banner unfurled before the dais read, “Export Justice: Not Bad Policy.”
The shouts continued for about five minutes as Frist seemed helpless in his efforts to regain control of the panel even after he said activists had made their point. After one protester said, “You have the floor, senator,” discussion on the panel began to proceed.
But as the members of Congress began to speak activists continued to criticize Republican members of the panel throughout the event — and not all the shouts were about U.S. aid to protect sex workers overseas against HIV/AIDS.
After Enzi gave his remarks recalling the process leading to passage of PEPFAR, protesters shouted, “What about epidemic at home? Where’s the Senate bill?” Enzi replied he’s voted twice to reauthorize funding for the Ryan White Care Act, which provides AIDS drugs to low-income people. The AIDS Institute later affirmed that Enzi twice voted for the measure in 2006 and 2009.
Frist also came to Enzi’s defense, saying the Wyoming senator has traveled to Africa seven times since his initial visit to monitor progress that U.S. global funds have been making on HIV/AIDS.
Rubio didn’t fare any better. When he began speaking, a member of the audience criticized the senator, saying the level of HIV criminalization is higher in Florida than any other part of the country. Another protester silently held up a sign reading, “Rubio Make Mitt Ends AIDS.”
Still, Rubio, a Tea Party favorite, seemed amenable to the United States confronting HIV/AIDS despite his general opposition to government spending, saying foreign aid represents about 1 percent of the U.S. budget and wouldn’t significantly reduce the deficit if taken away.
But the situation was different for Democratic lawmakers, particularly Lee, who last week introduced a bill in Congress called the “Ending HIV Act,” which, among other things, would repeal the ban prohibiting PEPFAR funds from going to sex workers. One protester before the dais held up a sign saying, “We <3 Barbra Lee.” Coons also didn’t endure significant barbs.
In her remarks on the panel, Lee touted the bipartisan work that has been done to confront HIV/AIDS, but said an expanded approach that includes drug users and sex workers is necessary because they represent the majority of people living with HIV. The lawmaker left immediately after her remarks to return to Capitol Hill for votes.
In the last 10 minutes of the discussion, Frist lost complete control of the event. When it became apparent that no time would be allocated for questions from the audience, protesters began to shout “Time for Q&A! Time for Q&A!”
Frist initially said he’d allow some time for questioning as panelists continued discussion, but the chants continued. Finally, as one male audience member demanded to talk and others chanted, “Let him speak,” Frist allotted him a full minute to talk, asking him to take up the full minute. The speaker, who didn’t identify himself, said he was an activist who hailed from Gambia, and accused panelists of allowing people in Africa to die, saying, “We could have saved lives if you allowed us to talk.”
The panel concluded shortly afterward. Protesters continued to chant as they exited the room together along with others.
Shawn Jain, a spokesperson for the conference, said the protesters and organizations with which they are affiliated do not face any consequences.
“The conference expects marches and other peaceful protests during AIDS 2012, including actions inside the conference venue,” Jain said. “AIDS activism has been very important to bringing about critical changes in how the world responds to HIV, and the conference endorses freedom of expression and peaceful protest as an essential principle in the fight against AIDS.”
Kelli Dorsey, one of the protesters and executive director of Different Avenues, said afterward the goal of the protest was to encourage Congress to lift the anti-prostitution pledge that is conditional for U.S. funds against AIDS under PEPFAR.
“What’s happened is some organizations — because of fear and because the guidelines are unclear — don’t provide the same services to sex workers, and therefore sex workers are marginalized from the health care systems,” Dorsey said.
Still, Dorsey expressed doubt that Congress will take action on this issue, saying, “I think it’s going to take a while for us to see action. I think Barbara Lee will put it in, [but] it’s going to be a slow build up because we have a very conservative Congress right now.”
Michael Tikili, a community organizer with an international AIDS activist group HealthGAP who held up the sign calling on Rubio to take action, said afterward Rubio “can actually influence” Romney because the senator is considered a contender as a vice presidential nominee.
“It’s really important for him to speak up on AIDS,” Tikili said. “The fear is that if Romney were to come into office, and he doesn’t have the same beliefs and intuition on AIDS funding, then we’re screwed.”
Tikili expressed confidence that Rubio got the message, saying, “I saw him look directly at me and frown.” And this message may have instigated progress. According to Tikili, Sally Canfield, Rubio’s deputy chief of staff, told the protesters after the event the senator would speak to Romney about issuing an AIDS strategy.
A Senate staffer, who spoke on condition of anonymity, characterized the situation slightly differently, but acknowledged Rubio agreed to talk to Romney on AIDS.
“After the panel, someone shouted out the general question, ‘Will you talk to Governor Romney about AIDS?'” the staffer said. “Marco said ‘sure.’ Nothing on a ‘national AIDS strategy’ though.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Protecting the trans community is not optional for elected allies and candidates
Trump’s ‘American people derangement syndrome’
